Synvista terminates development of all therapeutic candidates
This article was originally published in Scrip
Executive Summary
Synvista Therapeutics (formally known as Alteon) has terminated all ongoing clinical trials of its product candidates and will focus its resources on maximising the value of its diagnostic assets. The New Jersey-based company also voiced doubts over its ability to continue operating beyond the second quarter of this year, blaming its financial situation and the current economic climate.